Literature DB >> 22036303

Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Raminta Daniulaityte1, Russel Falck, Robert G Carlson.   

Abstract

BACKGROUND: There is growing evidence about illicit use of buprenorphine in the U.S. The study aims to: (1) identify prevalence and predictors of illicit buprenorphine use in a community sample of 396 young adult (18-23 years old) non-medical users of pharmaceutical opioids and (2) describe knowledge, attitudes and behaviors linked to illicit buprenorphine use as reported by a qualitative sub-sample (n=51).
METHODS: Participants were recruited using respondent-driven sampling. Qualitative interview participants were selected from the larger sample. The sample (n=396) was 54% male and 50% white; 7.8% reported lifetime illicit use of buprenorphine.
RESULTS: Logistic regression analysis results indicate that white ethnicity, intranasal inhalation of pharmaceutical opioids, symptoms of opioid dependence, and a greater number of pharmaceutical opioids used in lifetime were statistically significant predictors of illicit buprenorphine use. Qualitative interviews revealed that buprenorphine was more commonly used by more experienced users who were introduced to it by their "junkie friends." Those who used buprenorphine to self-medicate withdrawal referred to it as a "miracle pill." When used to get high, reported experiences ranged from "the best high ever" to "puking for days." Participants reported using buprenorphine/naloxone orally or by intranasal inhalation. Injection of buprenorphine without naloxone was also reported.
CONCLUSION: Our findings suggest that illicit buprenorphine use is gaining ground primarily among whites and those who are more advanced in their drug use careers. Continued monitoring is needed to better understand evolving patterns and trends of illicit buprenorphine use.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036303      PMCID: PMC3293107          DOI: 10.1016/j.drugalcdep.2011.09.029

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  38 in total

1.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France.

Authors:  Gwenaëlle Vidal-Trecan; Isabelle Varescon; Norbert Nabet; Alain Boissonnas
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

2.  Early and mid-adolescence risk factors for later substance abuse by African Americans and European Americans.

Authors:  Andres G Gil; William A Vega; R Jay Turner
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

3.  Racial/Ethnic differences in smoking, drinking, and illicit drug use among American high school seniors, 1976-89.

Authors:  J G Bachman; J M Wallace; P M O'Malley; L D Johnston; C L Kurth; H W Neighbors
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

4.  Respondent-driven sampling to recruit young adult non-medical users of pharmaceutical opioids: problems and solutions.

Authors:  Raminta Daniulaityte; Russel Falck; Linna Li; Ramzi W Nahhas; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

5.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

6.  A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.

Authors:  R E Johnson; T Eissenberg; M L Stitzer; E C Strain; I A Liebson; G E Bigelow
Journal:  Drug Alcohol Depend       Date:  1995-11       Impact factor: 4.492

7.  Tobacco, alcohol, and illicit drug use: racial and ethnic differences among U.S. high school seniors, 1976-2000.

Authors:  John M Wallace; Jerald G Bachman; Patrick M O'Malley; Lloyd D Johnston; John E Schulenberg; Shauna M Cooper
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

8.  Buprenorphine: "field trials" of a new drug.

Authors:  M Agar; P Bourgois; J French; O Murdoch
Journal:  Qual Health Res       Date:  2001-01

9.  Psychiatric and substance use disorders in South Florida: racial/ethnic and gender contrasts in a young adult cohort.

Authors:  R Jay Turner; Andres G Gil
Journal:  Arch Gen Psychiatry       Date:  2002-01

Review 10.  Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.

Authors:  T Peter Bridge; Paul J Fudala; Susan Herbert; Deborah B Leiderman
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

View more
  22 in total

1.  PREDOSE: a semantic web platform for drug abuse epidemiology using social media.

Authors:  Delroy Cameron; Gary A Smith; Raminta Daniulaityte; Amit P Sheth; Drashti Dave; Lu Chen; Gaurish Anand; Robert Carlson; Kera Z Watkins; Russel Falck
Journal:  J Biomed Inform       Date:  2013-07-25       Impact factor: 6.317

2.  "Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.

Authors:  Raminta Daniulaityte; Robert Carlson; Gregory Brigham; Delroy Cameron; Amit Sheth
Journal:  Am J Addict       Date:  2015-05-25

3.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

4.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

5.  Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.

Authors:  Pooja A Shah; Nancy L Sohler; Carolina López; Aaron D Fox; Chinazo O Cunningham
Journal:  J Opioid Manag       Date:  2013 Nov-Dec

6.  Self-management of buprenorphine/naloxone among online discussion board users.

Authors:  Shan-Estelle Brown; Frederick L Altice
Journal:  Subst Use Misuse       Date:  2014-06       Impact factor: 2.164

7.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

8.  Availability of buprenorphine on the Internet for purchase without a prescription.

Authors:  Marcus A Bachhuber; Chinazo O Cunningham
Journal:  Drug Alcohol Depend       Date:  2012-11-30       Impact factor: 4.492

9.  "I just wanted to tell you that loperamide WILL WORK": a web-based study of extra-medical use of loperamide.

Authors:  Raminta Daniulaityte; Robert Carlson; Russel Falck; Delroy Cameron; Sujan Perera; Lu Chen; Amit Sheth
Journal:  Drug Alcohol Depend       Date:  2012-11-30       Impact factor: 4.492

10.  Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Authors:  David Otiashvili; Gvantsa Piralishvili; Zura Sikharulidze; George Kamkamidze; Sabrina Poole; George E Woody
Journal:  Drug Alcohol Depend       Date:  2013-07-31       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.